Operon Discontinues Sale of Arrays in N. America Due to Concerns about Affy Patents

Jun 01, 2001

NEW YORK, June 1 - Qiagen subsidiary Operon said it has discontinued sales of its pre-fabricated, medium-density OpArrays in North America, due to concerns that they might infringe on Affymetrix’s patent portfolio.

Operon attorneys have interpreted Affymetrix’s patents as covering any array with over 60 unique features per square centimeter, while they previously interpreted Affymetrix’s patents as covering any array with over 400 features per square centimeter.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Getting It Early

Researchers have treated an X-linked genetic disease affecting three babies in utero, Stat News reports.

Food Bugs to Meet Sequencers

The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.

From Ancient Bathrooms

Researchers have sequenced samples from ancient toilets to study past eating habits and health, NPR reports.

This Week in Nature

In Nature this week: ash dieback disease fungal genome, and more.

Main menu